The Incident: Allegations of Misleading Social Media Promotions The U.S. Food and Drug Administration (FDA) has issued an untitled letter to Pfizer regarding its Facebook advertising campaigns for the cancer drug Adcetris. Regulatory officials accused the pharmaceutical giant of failing to adequately communicate the drug’s approved indication, contraindications, and significant safety risks.
Core Violations Identified by the FDA:
-
Misleading Indications: The video ads featured broad claims such as “Recently diagnosed with T-cell lymphoma?” The FDA ruled that these statements suggest Adcetris is approved for general treatment of T-cell lymphoma, whereas it is actually authorized only for specific subtypes and must be used in combination with specific chemotherapy regimens.
-
Lack of Specificity: Although some ads included clarifying text at the bottom, the agency concluded that this fine print failed to correct the overall misleading impression created by the prominent claims in the video.
-
Omission of Critical Risks: The ads failed to disclose a major contraindication involving concomitant use with bleomycin due to pulmonary toxicity. Furthermore, the promotion omitted information regarding potential fatal outcomes. This lack of transparency was deemed to minimize Adcetris’ risks and create a false sense of safety.
Regulatory Context The Adcetris notice is part of a significant escalation in the FDA’s enforcement of drug advertising rules. Since September, the agency has published 72 untitled letters a dramatic surge compared to just 35 letters issued over the preceding 12 years. Pfizer has been given 15 working days to respond with a plan to cease the misleading advertisement
Source: https://www.fiercepharma.com/marketing/pfizer-rebuked-fda-misleading-adcetris-ads-facebook